Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

JP Morgan Maintains Neutral on Benefitfocus, Lowers Price Target to $11

JP Morgan analyst Pinjalim Bora maintains Benefitfocus (NASDAQ:BNFT) with a Neutral and lowers the price target from $13 to $11.
byBenzinga Newsdesk
March 2, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

JP Morgan analyst Pinjalim Bora maintains Benefitfocus (NASDAQ:BNFT) with a Neutral and lowers the price target from $13 to $11.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Castle Biosciences To Present Data Supporting The Clinical Value Of Its Suite Of Skin Cancer Tests Through Multiple Oral Presentations At The 2022 American Society For Dermatologic Surgery Annual Meeting

By Benzinga Newsdesk
Today, 5:00 AM
Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, is presenting data highlighting its portfolio of skin cancer gene expression profile (GEP) tests at the

CSTL